US EditionPublished • loading... • Updated
Gilead Sciences to Present Promising Long-Term Efficacy Data at The Liver Meeting 2025 Amidst Mixed Financial Perform...
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Gilead Sciences to Present Promising Long-Term Efficacy Data at The Liver Meeting 2025 Amidst Mixed Financial Perform...
Gilead Sciences, Inc. (Nasdaq: GILD) is positioning itself at the forefront of liver disease research with its upcoming presentation at The Liver Meeting 2025, an event organized by the American Association for the Study of Liver Diseases (AASLD) scheduled for November 7-11 in Washington, D.C. The company plans to unveil notable findings from over 35 accepted abstracts, focusing on primary biliary cholangitis (PBC) and chronic hepatitis delta. A…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
